Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Daiichi Sankyo Co., Ltd. (OTC: DSKYF).

Full DD Report for DSKYF

You must become a subscriber to view this report.

Recent News from (OTC: DSKYF)

New Analysis Identifies Patient Populations With Cancer-associated VTE Who Could Benefit From Treatment With Oral, Once-daily LIXIANA®? (edoxaban)
MUNICH , August 6, 2018 /PRNewswire/ -- Hokusai-VTE CANCER study showed that oral edoxaban is non-inferior to subcutaneous injectable dalteparin, for the composite outcome of recurrent venous thromboembolism (VTE) and major bleeding in cancer-associated VTE     This anal...
Source: PR Newswire
Date: August, 06 2018 03:00
3 Things In Biotech, August 2: Japanese Drug Makers Rise And Fall
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Otsuka failure portends termination of an important AML study Company: Otsuka ( OTCPK:O...
Source: SeekingAlpha
Date: August, 02 2018 08:00
Daiichi Sankyo Co., Ltd. ADR 2018 Q1 - Results - Earnings Call Slides
The following slide deck was published by Daiichi Sankyo Co., Ltd. ADR in conjunction with their 2018 Q1 earnings Read more ...
Source: SeekingAlpha
Date: July, 31 2018 15:17
3 Things In Biotech, July 18: Cellectar Goes Boom And Psychs Out The Market
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Eisai posts favorable top-line data in obesity Company: Eisai ( OTCPK:ESALY ), Arena ( A...
Source: SeekingAlpha
Date: July, 18 2018 09:00
Learn How To Invest Against Acute Myeloid Leukemia, One Of The Fastest-Growing Cancer Markets
The most important weapon we as investors have in our arsenals is knowledge. Many of the people I've spoken with on Seeking Alpha and other forums have demonstrated keen awareness of the clinical pipeline for their company of interest. However, it is often difficult for them to place the resul...
Source: SeekingAlpha
Date: July, 09 2018 08:00
What Does Breakthrough Therapy Designation Really Mean For My Company?
Author's note: This article was presented early to subscribers of the Total Pharma Tracker , and they also got further insight into how best to use these tools in making investment decisions. The world of biotech investing revolves first and foremost around the regulatory agencies like th...
Source: SeekingAlpha
Date: June, 23 2018 09:00
Key events next week - healthcare
Noteworthy events during the week of June 10 - 16 for healthcare investors. More news on: Avenue Therapeutics, Cardinal Health Inc., La Jolla Pharmaceutical Co., Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: June, 08 2018 07:35
Daiichi Sankyo (DSNKY) Presents At 2018 American Society Of Clinical Oncology Annual Meeting - Slideshow
The following slide deck was published by Daiichi Sankyo Co., Ltd. ADR in conjunction with this Read more ...
Source: SeekingAlpha
Date: June, 04 2018 13:04
Daiichi Sankyo presents Phase 1 results of DS-8201 in patients with HER2 at 2018 ASCO annual meeting
Daiichi Sankyo Company ( OTCPK:DSKYF ) announces that long-term phase 1 safety and efficacy data for DS-8201, an investigational HER2-targeting antibody drug conjugate, in 241 heavily pretreated patients expressing breast, gastric and other solid cancers who received expansion doses of 5.4...
Source: SeekingAlpha
Date: June, 01 2018 09:00
Mining ASCO 2018's Gold, Part 5: There's A Lot To Look Forward To
The 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO 2018) is upon us, and it's about as close to Christmas as I get in my line of work. There's so much data presented here, with thousands of abstracts delivered to an audience of some 30,000 healthcare professionals, that...
Source: SeekingAlpha
Date: May, 27 2018 09:00


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on DSKYF.

About Daiichi Sankyo Co., Ltd. (OTC: DSKYF)

Logo for Daiichi Sankyo Co., Ltd. (OTC: DSKYF)

Founded on September , through the merger of Daiichi Pharmaceutical and Sankyo, Daiichi Sankyo delivers innovative products that enhance the lives of millions of people around the world. Our recent successes include the antihypertensive agent olmesartan Olmetec , launched in by Sankyo and now available in more than countries around the world the antiplatelet agent prasugrel Efient , launched in for patients with acute coronary syndrome ACS undergoing percutaneous coronary intervention PCI and edoxaban Lixiana , the first available factor Xa inhibitor in Japan, which launched in to help prevent venous thromboembolism VTE .


Contact Information



Current Management

  • Takashi Shoda / CEO

Current Share Structure

  • Market Cap: $25,942,725,040 - 05/14/2018
  • Authorized: 2,800,000,000 - 03/31/2013
  • Issue and Outstanding: 709,011,343 - 03/31/2013


Daily Technical Chart for (OTC: DSKYF)

Daily Technical Chart for (OTC: DSKYF)

Stay tuned for daily updates and more on (OTC: DSKYF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: DSKYF)

Do your DD and if you choose, be ready to go!


The Research: All source information contained in this email is from the public sources mentioned below.



Thank you

DD Report



Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in DSKYF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of DSKYF and does not buy, sell, or trade any shares of DSKYF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: